2024-10-01 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:** Pfizer Inc. is a global pharmaceutical company known for developing and manufacturing medicines and vaccines.

**Performance Summary:**

* **Return vs. S&P 500:** PFE's cumulative return of -11.79% is significantly lower than the S&P 500's (VOO) return of 133.28%. This represents a relative underperformance of -145.07%, which places it at the 0.84 percentile of its historical performance against the S&P 500.
* **Recent Price Movement:**  
    * Closing price: $29.18
    * 5-day moving average: $29.15
    * 20-day moving average: $29.22
    * 60-day moving average: $29.24
    * This suggests a stable price trend in the short-term, with slight downward pressure in the longer-term.

**Technical Indicators:**

* **RSI:** 46.6 - This indicates a neutral sentiment, not strongly overbought or oversold.
* **PPO:** -0.16 - This suggests a slight downward momentum, but not significant.
* **Delta_Previous_Relative_Divergence:** -2.42 - This indicates a short-term downward trend in relative performance compared to the S&P 500.
* **Expected Return:** 0.0% - This represents the maximum expected return over the next 5 years based on current investment.

**Recent Earnings and Outlook:**

| Date         | EPS  | Expected EPS |
|--------------|------|---------------|
| 2024-07-30  | 0.6  | 0.458        |
| 2024-05-01  | 0.82 | 0.516        |
| 2024-01-30  | 0.1  | -0.19        |
| 2023-10-31  | -0.17| -0.32        |
| 2023-08-01  | 0.67 | 0.56         |

The most recent earnings report for Q2 2024 showed an EPS of 0.6, exceeding the expected EPS of 0.458. This indicates a positive trend for Pfizer's earnings performance.

**News and Recent Issues:**

Pfizer's stock performance has been affected by factors like the decline in COVID-19 vaccine demand, competition in the pharmaceutical market, and ongoing price pressure. However, the company continues to invest in research and development for new treatments and therapies, particularly in areas like oncology and rare diseases.

* **Recent Market Outlook:**  FINBOLD's analyst opinions remain cautiously optimistic regarding PFE's future performance. They cite the company's strong product pipeline and focus on new innovations as potential drivers for growth. 
* **Analyst Opinions and Performance Highlights:** The consensus among analysts is that PFE is a "hold" with a potential upside.

**Overall Analysis:**

Pfizer Inc. (PFE) is currently underperforming the broader market, with a negative return compared to the S&P 500. While its recent earnings performance has been positive, the stock faces challenges from declining COVID-19 vaccine demand and market competition. Despite this, Pfizer's strong research and development efforts and diverse portfolio of products continue to offer potential for future growth. Investors should monitor the company's progress in new therapeutic areas and the ongoing performance of its existing products to assess future investment opportunities.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on individual research and consultation with a financial professional. 
